Access and Evidence
Writing the Value Story
When writing the value story for a new medicine, starting earlier in Development will make sure it’s a page-turner
More Access and Evidence Articles
Access and Evidence
Pragmatic Trials: RWE’s Hidden Gem
Pragmatic trials continue to be overlooked in the RWE space – particularly in the US. Can we expect to see wider stateside adoption?
Access and Evidence
The Naked Truth About Outcomes-Based Pricing
Hype around outcomes-based contracts has been doing the rounds for some time now, but is pharma delivering the goods?
Access and Evidence
Japan’s Perilous New Pricing Policy
The introduction of a new drug pricing reform in Japan has pharma up in arms. Are their fears justified?
Access and Evidence
Digital Health Tools Are No Fad
Data generating devices may seem gimmicky, but they are poised to transform healthcare
Access and Evidence
Overcoming The Access Hurdle
If pharma is to keep whizzing ahead, it needs to rethink its approach to market access
Access and Evidence
Could EHRs Boost Clinical Trial Recruitment?
Patient recruitment for clinical trials is commonly accepted to be a herculean task. A new platform could make the process a lot quicker and easier – and, crucially, not at the expense of data privacy
Access and Evidence
Raising The Curtain On Real-World Evidence
RWE continues to animate expectations far and wide, but its success calls for level-headed pragmatism
Access and Evidence
Bridging The Evidence Gap
AstraZeneca's Head of Real World Evidence shares the story behind AZ's seminal RWE study and casts his projections on the future
Access and Evidence
Out With The OId, In With The New
Pharma must seek alternative pricing models if it is to become a greater dynamic force